The emergence of drug resistant HIV variants and novel anti-retroviral therapy

Asian Pacific Journal of Tropical Biomedicine

Volumn 3, Issue 7, 2013, Pages 515-522

  Paydary, Koosha ^a,b   Khaghani, Parisa ^a,b   Emamzadeh Fard, Sahra ^a,b   Alinaghi, Seyed Ahmad Seyed ^a   Baesi, Kazem ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Developed world; Developing world; Drug resistance; Evolution; HIV infection

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ARTICLE; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ECONOMIC ASPECT; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL HISTORY; MOLECULAR EVOLUTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VIRUS REPLICATION; VIRUS STRAIN;

DEVELOPED WORLD; DEVELOPING WORLD; DRUG RESISTANCE; EVOLUTION; HIV INFECTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MEDICATION ADHERENCE; PREVALENCE; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH;

EID: 84879700319     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2221-1691(13)60106-9     Document Type: Article

References (72)

1. Gandon S, Buckling A, Decaestecker E, Day T Host-parasite coevolution and patterns of adaptation across time and space. J Evol Biol 2008, 21(6):1861-1866.
2. Schmid-Hempel P, Ebert D On the evolutionary ecology of specific immune defence. Trends Ecol Evol 2003, 18(1):27-32.
3. Soler JJ, Martanez JG, Soler M, Muller AP Coevolutionary interactions in a host parasite system. Ecol Lett 2008, 4(5):470-476.
4. Nesse RM, Foxman B Evolutionary approaches to sexually transmitted infections. Ann N Y Acad Sci 2011, 1230(1):1-3.
5. Antonovics J, Boots M, Abbate J, Baker C, McFrederick Q, Panjeti V Biology and evolution of sexual transmission. Ann N Y Acad Sci 2011, 1230(1):12-24.
6. Nahmias S, Nahmias D Society, sex, and STIs: human behavior and the evolution of sexually transmitted diseases and their agents. Ann N Y Acad Sci 2011, 1230(1):59-73.
7. World Health Organization AIDS epidemic update 2009, World Health Organization, Geneva.
8. Paydary K, Emamzadeh-Fard S, Khorshid HR, Kamali K, Seyed Alinaghi S, Mohraz M Safety and efficacy of setarud (IMOD TM) among people living with HIV/AIDS: A review. Rec Pat Antiinfect Drug Discov 2012, 7(1):66-72.
9. Skar H, Hedskog C, Albert J HIV-1 evolution in relation to molecular epidemiology and antiretroviral resistance. Ann N Y Acad Sci 2011, 1230(1):108-118.
10. Sharp PM, Hahn BH The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci 2010, 365(1552):2487-2494.
11. Tebit DM, Arts EJ Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011, 11(1):45-56.
12. Shi B, Kitchen C, Weiser B, Mayers D, Foley B, Kemal K, et al. Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology 2011, 404(1):5-20.
13. Johnson VA, Calvez V, Ganthard HF, Paredes R, Pillay D, Shafer R, et al. Update of the drug resistance mutations in HIV-1. HIV Med 2011, 18:156-163.
14. Simon Loriere E, Holmes EC Why do RNA viruses recombine?. Nat Rev Microbiol 2011, 9(8):617-626.
15. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 2010, 84(19):9864-9878.
16. Brown RJ, Peters PJ, Caron C, Gonzalez-Perez MP, Stones L, Ankghuambom C, et al. Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J Virol 2011, 85(12):6024-6037.
17. Lauring AS, Andino R Quasispecies theory and the behavior of RNA viruses. PLoS Path 2011, 6(7):1001005.
18. Moir S, Chun TW, Fauci AS Pathogenic mechanisms of HIV disease. Ann Rev Path 2011, 6:223-248.
19. Archer J, Pinney JW, Fan J, Simon-Loriere E, Arts EJ, Negroni M, et al. Identifying the important HIV-1 recombination breakpoints. PLoS Comput Biol 2008, 4(9):1000178.
20. Whitney JB, Lim SY, Wainberg MA Evolutionary mechanisms of retroviral persistence. AIDS Rev 2011, 13(4):234-239.
21. van Marle G, Church DL, Nunweiler KD, Cannon K, Wainberg MA, Gill MJ Higher levels of zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology 2010, 7(1):74.
22. Neogi U, Shet A, Sahoo PN, Bontell I, Ekstrand ML, Banerjea AC, et al. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. J Int AIDS Soc 2013, 16:18472.
23. Lever RA, Lever AML Intracellular defenses against HIV, viral evasion and novel therapeutic approaches. J Formos Med Assoc 2011, 110(6):350-362.
24. Skoura L, Metallidis S, Buckton AJ, Mbisa JL, Pilalas D, Papadimitriou E, et al. Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece. J Antimicrob Chemother 2011, 66(12):2831-2837.
25. Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, Cai F, et al. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol 2011, 85(13):6403-6415.
26. Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, Yazdani Z, et al. Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch Virol 2010, 155(3):329-334.
27. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection. JAMA 2012, 304(3):321-333.
28. Alteri C, Svicher V, Gori C, Arrigo DR, Ciccozzi M, Ceccherini-Silberstein F, et al. Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients nave to the antiretroviral drugs. BMC Infect Dis 2009, 9(1):111.
29. World Health Organization. Report of a WHO consultation. Rome: World Health Organization, Department of Communicable Disease Surveillance and Response. 10-11 October 2000, 2001.
30. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, US-2006. AIDS 2010, 24(8):1203.
31. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010, 201(5):662-671.
32. Buendia P, Cadwallader B, DeGruttola V A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics 2009, 25(19):2522-2529.
33. Cortez KJ, Maldarelli F Clinical management of HIV drug resistance. Viruses 2011, 3(4):347-378.
34. Briz V, Palladino C, Navarro ML, Jimenez de Ory S Etravirine based highly active antiretroviral therapy in HIV infected paediatric patients. HIV Med 2011, 12(7):442-446.
35. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure a systematic review and pooled analysis. JAMA 2011, 305(13):1327-1335.
36. Tang MW, Shafer RW HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012, 72(9):1-25.
37. Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, et al. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. J Antimicrob Chemother 2012, 67(4):988-994.
38. Kumari G, Singh KR Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr Pharm Des 2006, 19(10):1767-1783.
39. Li JZ, Kuritzkes DR Clinical implications of HIV-1 minority variants. Clin Infect Dis 2013, 56(11):1667-1674.
40. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary Elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013, 57(6):2654-2663.
41. Rouzine IM, Weinberger LS The quantitative theory of within-host viral evolution. J Stat Mech 2013, 2013(1):01009.
42. Carvajal-Rodraguez A, Crandall KA, Posada D Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect Genet Evol 2007, 7(4):476-483.
43. Giorgi EE, Korber BT, Perelson AS, Bhattacharya T Modeling sequence evolution in HIV-1 infection with recombination. J Theor Biol 2013, 21:82-93.
44. Bershteyn A, Eckhoff PA A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Syst Biol 2013, 7(1):11.
45. Xiao Y, Miao H, Tang S, Wu H Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models. Adv Drug Deliv Rev 2013 Apr 17, [Epub ahead of print]. 10.1016/j.addr.2013.04.005.
46. Bontell I, Cuong DD, Agneskog E, Diwan V, Larsson M, Sannerborg A Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. Infect Genet Evol 2012, 12(2):448-452.
47. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 6:1250-1258.
48. von Wyl V, Yerly S, Boni J, Shah C, Cellerai C, Klimkait T, et al. Incidence of HIV-1 drug resistance among antiretroviral treatment naive individuals starting modern therapy combinations. Clin Infect Dis 2012, 54(1):131-140.
49. de Mulder M, Yebra G, Navas A, Martin L, de Jose MI, Navarro ML, et al. Trends in drug resistance prevalence in HIV-1 infected children in Madrid: 1993 to 2010 analysis. Pediatr Infect Dis J 2012, 31(11):213-221.
50. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347(6):385-394.
51. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jargensen LB, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005, 40(5):505-511.
52. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008, 48(3):324-333.
53. Vercauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009, 200(10):1503-1508.
54. Oette M, Reuter S, Kaiser R, Lengauer T, Fantkenheuer G, Knechten H, et al. Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany. Intervirology 2012, 55(2):154-159.
55. Karlsson A, Biokman P, Bratt G, Ekvall K, Gisslen M, Sinnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2012. PLoS One 2012, 7(3):33484.
56. Frentz D, Boucher CA, van de Vijver DA Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012, 14(1):17-27.
57. Avila-Raos S, Garcia-Morales C, Garrido-Rodraguez D, Ormsby CE, Hernandez-Juan R, Andrade-Villanueva J, et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS One 2011, 6(11):27812.
58. Soria J, Bull M, Mitchell C, La Rosa A, Dross S, Kraft K, et al. Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru. AIDS Res Hum Retroviruses 2012, 28(4):333-338.
59. Yebra G, de Mulder M, Perez-Elias MJ, Perez-Molina JA, Galan JC, et al. Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One 2011, 6(10):26757.
60. Emamzadeh-Fard S, Fard SE, Seyed Alinaghi S, Paydary K Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: A review. Infect Disord Drug Targets 2012, 12(5):346-356.
61. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SHR, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One 2013, 8(4):61864.
62. Amon JJ Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Global Health 2008, 4:5.
63. Alinaghi SAS, Paydary K, Emamzadeh-Fard S, Mohraz M Treatment with IMODTM as a novel immune modulator in HIV positive patients. J AIDS Clin Res 2013, 3(180):223-228.
64. Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F Development of an alpha screen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen 2012, 17(5):618-628.
65. Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 2009, 53(3):1116-1123.
66. Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother 2011, 55(2):722-728.
67. Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, Fang H, et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother 2011, 55(2):729-737.
68. Clavel F, Hance AJ HIV drug resistance. N Engl J Med 2004, 350(10):1023-1035.
69. Paydary K, Esmaeeli S, Seyed Alinaghi S, Rouzrokh P, Emamzadeh-Fard S Emerging HIV drug resistance in the resource-poor world: challenges and strategies. J AIDS Clin Res 2013, 5:2.
70. Ji H, Massa N, Tyler S, Liang B, Li Y, Merks H, et al. HIV drug resistance surveillance using pooled pyrosequencing. PLoS One 2012, 5(2):9263.
71. Goldberg DE, Siliciano RF, Jacobs JWR Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 2012, 148(6):1271-1283.
72. Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012, 54(11):1660-1669.